I-Mab (IMAB) announced its new business model, focused on its global capabilities built to accelerate access to medicines and to enable broad strategic growth. The company announced its intention to pursue a Hong Kong IPO through dual listing on Nasdaq and Hong Kong Stock Exchange. The company intends to operate under the new name of NovaBridge Biosciences.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I MAB (ADS) trading halted, news pending
- I-Mab Reports H1 2025 Financial Results Amid Strategic Shift
- I-Mab initiated with an Outperform at Leerink
- I-Mab to Vote on Name Change to NovaBridge Biosciences
- Trump Trade: Offshore wind seen with no future in the U.S. under Trump